Minoxidil may inhibit androgenreceptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.
AH-001 is a new topical treatment designed to degrade androgenreceptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The GT20029 tincture, a topical androgenreceptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgenreceptors. Concerns include its staining properties and unclear topical absorption.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgenreceptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.